PACIRA BIOSCIENCES INC (PCRX)
US6951271005 - Common Stock
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting --
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting --...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences Reports Third Quarter 2024 Financial Results
Pacira BioSciences Reports Third Quarter 2024 Financial Results
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry...
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter...
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA,...
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX),...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain...
Bargain Hunters Take Note: Insider Cluster-Buying At PCRX
Will Insiders Be Tempted To Buy More PCRX At The New 52-Week Low?
Noteworthy Monday Option Activity: WING, OXY, PCRX
Pacira BioSciences is Now Oversold (PCRX)
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain...
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pacira BioSciences (NASDAQ:PCRX) just reported results for the second quarter o...
Pacira BioSciences Reports Second Quarter 2024 Financial Results
Pacira BioSciences Reports Second Quarter 2024 Financial Results
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader...
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
First Week of September 20th Options Trading For Pacira BioSciences (PCRX)
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024